Date Filed | Type | Description |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
06/29/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/12/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/05/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
05/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
04/05/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
04/04/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
03/31/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/22/2023 |
8-K
| Investor presentation |
03/13/2023 |
8-K
| Other Events Interactive Data |
03/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/24/2023 |
SC 13D
| FiveT Investment Management Ltd reports a 4.8% stake in INHIBIKASE THERAPEUTICS INC |
02/08/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
02/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
02/07/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
01/31/2023 |
SC 13D
| FiveT Investment Management Ltd reports a 4.1% stake in INHIBIKASE THERAPEUTICS INC |
01/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
01/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Pre-Funded Warrant",
"Form of Private Common Warrant",
"Form of PIPE Pre-Funded Warrant",
"Form of PIPE Common Warrant",
"Form of Placement Agent Warrant",
"Opinion of McDermott Will & Emery LLP",
"Securities Purchase Agreement, (Registered Direct)",
"Securities Purchase Agreement, (PIPE)",
"Registration Rights Agreement, (PIPE)",
"Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules BOSTON and ATLANTA, January 25, 2023 — Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease , Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into definitive agreements for the issuance and sale of 6,744,187 of its shares of common stock at a purchase price of $0.86 per share in a registered direct offering. In a concurrent private placement, Inhibikase has also agreed to issue and sell 4,883,721 of its shares of common stock , at the same purchase price as i..." |
|
01/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
01/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
11/17/2022 |
8-K
| Quarterly results |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/07/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/16/2022 |
8-K
| Investor presentation |
09/01/2022 |
8-K
| Quarterly results |
08/15/2022 |
8-K
| Quarterly results |
08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
07/28/2022 |
8-K
| Quarterly results |
06/29/2022 |
8-K
| Quarterly results |
06/22/2022 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
|